Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Mantle Cell Lymphoma Chronic Disease Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoma Lymphoma, Mantle-Cell Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Alta Bates Cancer Center, Berkeley, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma
at least one prior cytotoxic chemotherapy regimens
measurable disease
adequate bone marrow, liver and kidney function
ECOG PS 0-2

Exclusion criteria

prior treatment with elsamitrucin
prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment
HIV positive or known AIDS syndrome
uncontrolled medical disease or psychiatric condition/s

Treatment and study plan

Elsamitrucin

Drug

Sponsors and collaborators

Lead sponsor

Spectrum Pharmaceuticals, Inc

Industry

Registry information

Official study title

A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Important dates

Study start: 2004
Study completion: 2006
First posted: Aug 25, 2004
Registry last updated: Jan 15, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed